Hepatitis C virus kinetics and optimized therapy in DAA treatment
| Project/Area Number |
15K19586
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Infectious disease medicine
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
Eiichi Ogawa 九州大学, 医学研究院, 助教 (70621283)
|
|---|
| Research Collaborator |
NORIHIRO Furusyo 九州大学, 大学院・医学研究院 感染制御医学分野, 准教授 (10346786)
MASAYUKI Murata 九州大学, 病院・総合診療科, 講師
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
|
|---|
| Keywords | C型肝炎ウイルス / リアルタイムPCR法 / DAA / Ｃ型肝炎ウイルス / Real-time PCR法 / インターフェロン / プロテアーゼ阻害剤 |
|---|
| Outline of Final Research Achievements |
The study was carried out to compare the ability of two HCV RNA assays (TaqMan and AccuGene assays) to evaluate the impact of hepatitis C virus (HCV) kinetics on the outcome of patients treated with triple therapy or interferon-free sofosbuvir-based therapy.
In triple therapy, the time HCV RNA became undetectable by the AccuGene assay was associated with treatment outcome for difficult-to-treat group, such as patients with advanced fibrosis, IL28B TG/GG genotype (rs8099917), and prior non-responders. In sofosbuvir-based therapy, the time at which HCV RNA became target not detected was not associated with treatment outcome by either the AccuGene or TaqMan assay.
|
Report
(3 results)
Research Products
(5 results)
